Login to Your Account



Ipsen Buys Botulinum Toxin Specialist Syntaxin for $206M

By Nuala Moran
Staff Writer

Wednesday, July 17, 2013
LONDON – The UK botulinum toxin specialist Syntaxin Ltd. is to be acquired by research partner and equity investor Ipsen SA in a deal that potentially is worth €158 million (US$205.8 million), with €28 million to be paid up front, and the remainder tied to development and commercialization milestones.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription